1. Home
  2. CSWC vs AUPH Comparison

CSWC vs AUPH Comparison

Compare CSWC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

N/A

Current Price

$21.72

Market Cap

1.3B

ML Signal

N/A

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

N/A

Current Price

$14.38

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CSWC
AUPH
Founded
1961
1993
Country
United States
Canada
Employees
30
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CSWC
AUPH
Price
$21.72
$14.38
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$23.50
$17.25
AVG Volume (30 Days)
577.3K
895.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
11.63%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
$16.83
$17.35
Revenue Next Year
$10.26
$15.66
P/E Ratio
$12.65
$7.15
Revenue Growth
N/A
20.38
52 Week Low
$17.47
$6.83
52 Week High
$23.84
$16.54

Technical Indicators

Market Signals
Indicator
CSWC
AUPH
Relative Strength Index (RSI) 36.18 47.32
Support Level $21.37 $13.52
Resistance Level $23.06 $15.23
Average True Range (ATR) 0.54 0.57
MACD -0.09 0.04
Stochastic Oscillator 20.25 49.42

Price Performance

Historical Comparison
CSWC
AUPH

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: